Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Apr 10:2013:256426.
doi: 10.1155/2013/256426. eCollection 2013.

Mild Hypertransaminasemia in Primary Care

Affiliations
Review

Mild Hypertransaminasemia in Primary Care

Said A Al-Busafi et al. ISRN Hepatol. .

Abstract

The liver enzymes, alanine transaminase (ALT) or aspartate transaminase (AST), are commonly used in clinical practice as screening as well as diagnostic tests for liver diseases. ALT is more specific for liver injury than AST and has been shown to be a good predictor of liver related and all-cause mortality. Asymptomatic mild hypertransaminasemia (i.e., less than five times normal) is a common finding in primary care and this could be attributed to serious underlying condition or has transient and benign cause. Unfortunately, there are no good literatures available on the cost-effectiveness of evaluating patients with asymptomatic mild hypertransaminasemia. However, if the history and physical examination do not suggest a clear cause, a stepwise approach should be initiated based on pretest probability of the underlying liver disease. Nonalcoholic fatty liver disease is becoming the most common cause of mild hypertransaminasemia worldwide. Other causes include alcohol abuse, medications, and hepatitis B and C. Less common causes include hemochromatosis, α1-antitrypsin deficiency, autoimmune hepatitis, and Wilson's disease. Nonhepatic causes such as celiac disease, thyroid, and muscle disorders should be considered in the differential diagnosis. Referral to a specialist and a possible liver biopsy should be considered if persistent hypertransaminasemia for six months or more of unclear etiology.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Management algorithm of mild hypertransaminasemia [1, 4, 5].

Similar articles

Cited by

References

    1. Pratt D. S., Kaplan M. M. Evaluation of abnormal liver-enzyme results in asymptomatic patients. The New England Journal of Medicine. 2000;342(17):1266–1271. doi: 10.1056/NEJM200004273421707. - DOI - PubMed
    1. Ioannou G. N., Boyko E. J., Lee S. P. The prevalence and predictors of elevated serum aminotransferase activity in the United States in 1999–2002. American Journal of Gastroenterology. 2006;101(1):76–82. doi: 10.1111/j.1572-0241.2005.00341.x. - DOI - PubMed
    1. Sherwood P., Lyburn I., Brown S., Ryder S. How are abnormal results for liver function tests dealt with in primary care? Audit of yield and impact. British Medical Journal. 2001;322(7281):276–278. - PMC - PubMed
    1. Green R. M., Flamm S. AGA technical review on the evaluation of liver chemistry tests. Gastroenterology. 2002;123(4):1367–1384. doi: 10.1053/gast.2002.36061. - DOI - PubMed
    1. Minuk G. Y. Canadian association of gastroenterology practice guidelines: evaluation of abnormal liver enzyme tests. Canadian Journal of Gastroenterology. 1998;12(6):417–421. - PubMed

LinkOut - more resources